Dr. Weber on Immunologic Activities of Targeted Agents

Jeffrey S. Weber, MD, PhD, medical oncologist, Department of Cutaneous Oncology, director, Donald A. Adam Comprehensive Melanoma Research Center, Moffitt Cancer Center, discusses the immunologic activities of targeted agents for the treatment of melanoma.

There has been work in the past 3-4 years suggesting that a targeted agent that should have no immunologic activity will generate an influx of immune cells into the tumor. The trick when dealing with these hidden immunologic activities of non-immune drugs is to take advantage and use them in the proper way.